Advertisement

ADVERTISEMENT

Paresh Vyas

A Phase 3, Randomized Trial of Magrolimab in Combination With Venetoclax and Azacitidine in Previously Untreated Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy (ENHANCE-3)
Introduction:
11/04/2022
Tolerability and Efficacy of the First-in-Class Anti-CD47 Antibody Magrolimab Combined With Azacitidine in Frontline Patients With TP53-Mutated Acute Myeloid Leukemia: Phase 1b Results
Introduction:
11/04/2022
A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine in Previously Untreated Patients With TP53-Mutant Acute Myeloid Leukemia
Introduction:
11/04/2022
Magrolimab in Combination With Azacitidine for Patients With Untreated Higher-Risk Myelodysplastic Syndromes: 5F9005 Phase 1b Study Results
Introduction:
11/04/2022

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

November 6 ⁠–⁠ November 8
NEI Congress
November 7 ⁠–⁠ November 10
WoundCon
November 8
ECS
November 8 ⁠–⁠ November 10
Dermatology Week
November 13 ⁠–⁠ November 16
Psych Congress Primary Care Online Series
November 14 ⁠–⁠ November 15
November 23 ⁠–⁠ November 24
December 4 ⁠–⁠ December 5
Great Debates & Updates in Diabetic Foot
December 6 ⁠–⁠ December 7
AIBD logo
December 9 ⁠–⁠ December 11
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use